LRP5 (LDL receptor related protein 5; HGNC:6697, NCBI Gene 4041) is the gene on chromosome 11q13.2 encoding LRP5 — the co-receptor (with Frizzled) that delivers Wnt signals to the β-catenin destruction complex's Dishevelled-mediated inhibition: the skeletal Wnt pathway's gate. Its loss-of-function causes osteoporosis-pseudoglioma syndrome; its gain-of-function (the high-bone-mass mutations, e.g. G171V) produces vertebrae of near-record density — bone-mass genetics' cleanest lesson.
Approved Symbol
LRP5 (HGNC:6697)
Chromosomal Locus
11q13.2
Encoded Product
LRP5 — a 180-kDa single-pass Wnt co-receptor (1,615 aa)
Primary Pathway
Wnt → Frizzled + LRP5/6 → Dishevelled → β-catenin stabilized → the osteoblast program (see CTNNB1)
Genomic organization: 23 exons; the extracellular EGF-like domains carry the loss- and gain-of-function variants — the G171V-class gains blocking DKK/SOST inhibitor docking (sclerostin's target site, the osteoporosis drug romosozumab's own target).
Expression: Osteoblast-lineage cells (the bone-forming target), plus eye development's vascular role (the pseudoglioma of the loss syndrome) and gut enteroendocrine cells.
Molecular Function & Pathways
Skeletal Wnt signaling: LRP5-Frizzled co-reception activating the canonical Wnt cascade in osteoblasts → osteoprotegerin up, osteoclastogenesis restrained, bone formation up — the pathway that bone-mass genetics and teriparatide-adjacent osteobiology converged on.
Modifier genetics: Common LRP5 variants among the strongest osteoporosis-GWAS signals (bone-mineral-density variance); DKK1 and SOST as the pathway's druggable brakes — sclerostin inhibition's mechanism, which grew directly from the LRP5 genetics: block the brake the high-bone-mass mutations had already blocked.
Clinical & Therapeutic Significance
Clinical genetics: Autosomal recessive loss-of-function — osteoporosis-pseudoglioma syndrome (juvenile osteoporosis + eye vascularization); autosomal dominant gain-of-function — high bone mass, discovered kindreds with extraordinary density and fracture resistance.
Therapeutics: The LRP5 pathway's brakes as drug targets — romosozumab (anti-sclerostin, the anabolic osteoporosis drug built from this genetics); BMD-GWAS-guided risk assessment.